Explore the options in chronic lymphocytic leukemia (CLL) targeted therapy. Experts discuss BTK inhibitors, PI3K inhibitors, and BCL2 inhibitors as monotherapy treatment. The discussion concludes with a focus on the trials investigating targeted agents in combination with each other, with second-generation monoclonal antibodies, and with immunotherapy. Don’t miss out on the updates.
1.0 AMA PRA Category 1 Credit™
Mar 29, 2019
Mar 29, 2020
Jacqueline C. Barrientos, MD, MSZucker School of Medicine at Hofstra/Northwell
Lake Success, New York, United States
Barbara Eichhorst, MD, PhDUniversity Hospital Cologne
- Targeted agents in CLL
- CLL combination therapy
This educational activity is intended for hematologists, oncologists, and other healthcare professionals involved in the management of CLL.
After successful completion of this educational activity, participants should be able to:
- Describe recent data examining current and emerging agents under investigation in both treatment-naïve and relapsed/refractory CLL
- Select appropriate treatment for patients with CLL based on patient characteristics, and disease- and treatment-related factors
- Implement clinical protocols to detect and appropriately manage treatment-related toxicities
This educational activity is supported by a grant from AbbVie.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Estimated time to complete activity: 1 hour
To contact Postgraduate Institute for Medicine please visit www.pimed.com.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Barrientos has disclosed that she has received consulting fees from Genentech, Gilead, Janssen, and Pharmacyclics/AbbVie. She has also performed contracted research for Pharmacyclics/AbbVie. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Eichhorst has disclosed that she has received consulting fees from AbbVie, Celgene Corporation, Gilead, Janssen, Novartis Oncology, and Roche. She has performed contracted research for AbbVie, Gilead, Janssen, and Roche.
Postgraduate Institute for Medicine planners and managers have disclosed no relevant financial relationships.
The employees of prIME Oncology have disclosed:
- Ronald Viggiani, MD (medical director) – worked on non-CME certified projects in the last 12 months supported by Pfizer
- Briana Betz, PhD (scientific content manager) – worked on non-CME certified projects in the last 12 months supported by Helsinn Healthcare, ImmunoGen, Karyopharm Therapeutics, Novartis, Pfizer, and TG Therapeutics
- Susan McKinney – no relevant financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.